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0 and 42 post-infection (p.i.), and subgroups of 6-18 mice
were bled at d7, 14, 21, and 28 p.i. for the measurement
of total, HDL, and LDL cholesterol (Chl), and triglyceride
levels. At d42 p.i. all surviving mice were sacriﬁced and
brains harvested for cyst enumeration. The experiment was
performed twice, and the shown data represent their cumu-
lative results.
Results: A signiﬁcant decrease (p < 0.05) in total Chl and
HDL occurred in infected vs. control mice of d14, 21 and 42
p.i. Conversely, LDL levels were unaltered until d42, when
LDL signiﬁcantly increased (p < 0.05). While the number of
cysts at the end of the experiment varied greatly (range
20—7460 per brain), a positive correlation (p = 0.023) was
obtained between cyst counts >300 (in 44% mice) and LDL
level.
Conclusion: Acute T. gondii infection apparently induces
a decrease in reverse Chl transport. While this decrease per-
sists up to chronicity it is only then that an increase in direct
Chl transport occurs. To clarify the mechanisms underlying
T. gondii-induced lipid metabolism alterations, our current
research focuses on the analysis of Chl receptors (SR-BI and
LDL-R), Apo A-IV, Apo B-100, and adiponectin, as well as the
corresponding candidate genes.
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Background: We assessed the immune response to Pen-
taxim when given as a booster dose in Thai children primed
with a diphtheria, tetanus, acellular pertussis, inactivated
poliovirus, hepatitis B, Hib-conjugate combination vaccine
in infancy.
Methods: DTaP-IPV-Hib vaccine (PentaximTM, Sanoﬁ Pas-
teur AcXim family vaccine) was given as a 4th (booster) dose
at 18—24 months of age to 156 children previously primed
at 2, 4 and 6 months of age with a hexavalent vaccine con-
taining the same vaccine antigens plus hepatitis B. A dose
of monovalent hepatitis B vaccine was also given at birth.
Antibody titers were measured just before and one month
after the booster vaccination. Reactogenicity and safety
were evaluated from parent reports.
Results: Seroprotection rates, approximately one year
post-primary vaccination remained high. Anti-PRP GMT
increased from 1.6 to 58.0g/mL pre- to post-booster
vaccination. GMTs for PT and FHA increased from 3.8 to
181.2 EU/mL and from 18.0 to 289.7 EU/mL respectively.
GMTs for each poliovirus type also strongly increased from
pre- to post-booster dose. Vaccine reactogenicity was low.
There were only two severe local reactions and two subjects
had severe fever possibly related to vaccination, all of which
resolved.
Conclusion: Pentaxim induced a strong booster response
to all the vaccine antigens at 18-24 months and was well
tolerated. The timing of this booster was appropriate as pre-
booster antibody titres and seroprotection rates remained
satisfactory. Booster vaccination during from the second
year of life has been recommended and is the practice in
many different countries, with the aim of expanding control
of childhood infectious diseases including pertussis and Hib.
[study E2I36]
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Background: We evaluated the immunogenicity and
safety of a pentavalent acellular pertussis, inactivated
poliovirus-based combination vaccine in a tropical country,
with concomitant administration of hepatitis B vaccine.
Methods: The pentavalent combination vaccine
PentaximTM (sanoﬁ pasteur, AcXim family vaccine), con-
taining diphtheria, tetanus, acellular pertussis, inactivated
poliovirus, and Haemophilus inﬂuenzae type B conjugate
(PRP-T) antigens was given to 186 Thai infants at 2, 4 and
6 months of age. Hepatitis B vaccine was given at birth,
2 and 6 months of age, following the national schedule.
Immunogenicity data from French infants vaccinated with
the same schedule was used as a reference. Antibody
titers were measured one month after completing the
three-dose primary vaccination. Reactogenicity and safety
were evaluated from parent reports.
Results:After the third dose, anti-PRP≥ 1.0g/mL
was observed in 96.5% (95%CI 92.6; 98.7) of subjects
(GMT= 9.3g/mL). Anti-polio GMTs were 120, 1553 and
3003 1/dil U. for poliovirus types 1, 2 and 3 respectively.
Two-fold increase from pre- to post-vaccination in anti-
body concentration were 97.6% and 97.7% for PT and FHA
respectively. Anti-PT and anti-FHA GMTs increased from 2.8
to 176 EU/mL, and from 3.7 to 119 EU/mL respectively.
Anti-pertussis PT and FHA antibody titers≥ 25 EU/mL were
observed in 100% and 98.8% of subjects, respectively. Hep-
atitis B seroprotection rate (anti-HBs≥ 10mIU/mL) was 100%
(95%CI 97.5%; 100%) with a GMT of 1561mIU/mL (95%CI 136;
1783mIU/mL). Vaccine reactogenicity was low, with fewer
than 1% of vaccine doses eliciting a severe solicited adverse
reaction. No case of hypotonic hyporesponsive episode was
reported. There were no drop outs because of adverse
events.
Conclusion: The immunogenicity of Pentaxim, when given
at 2, 4 and 6months of age in the tropical climate of Thailand
was high, and similar to responses in European infants. The
vaccine was well tolerated even when given concomitantly
at separate sites with hepatitis B vaccine [NCT00254969].
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